Skip to main content
    Questions About Kratom or 7-OH? Find Treatment OptionsConfidential Treatment NavigationTalk With a Treatment NavigatorVerify Insurance Coverage
    Get Help Now
    844-DETOXNY
    Home›Articles›7-OH Drug Classification

    7-Hydroxymitragynine (7-OH): Regulatory Developments and Clinical Considerations

    FDA recommendation for Schedule I classification and state-level regulatory responses

    BZ

    Written by

    Benjamin Zohar, NCACIP

    Nationally Certified Advanced Clinical Intervention Professional

    EZ

    Edited by

    Ezra Zohar, M.S. Ed.

    Editorial Director

    BM

    Medically Reviewed by

    Brandon McNally, RN

    Medical Reviewer, ICU Critical Care Nurse

    Published: November 25, 2025
    15 min read

    In July 2025, the U.S. Food and Drug Administration (FDA) formally recommended that the Drug Enforcement Administration (DEA) classify 7-hydroxymitragynine (7-OH) as a Schedule I controlled substance [1]. This recommendation reflects federal concerns about synthetic and concentrated forms of this compound, which are chemically distinct from traditional kratom leaf products.

    Key Points

    • Federal Recommendation: FDA has recommended DEA classify 7-OH as Schedule I [1]
    • State Actions: Florida classified 7-OH as Schedule I in August 2025 [2]; New York legislation is under review
    • Local Regulations: Suffolk County, NY restricts sales to individuals 21 and older (Local Law No. 37-2016) [3]
    • Clinical Concerns: Limited evidence exists on long-term effects; reports of dependence and withdrawal have been documented [4]
    • Product Distinction: Synthetic/concentrated 7-OH differs significantly from traditional kratom leaf

    What is 7-Hydroxymitragynine?

    7-hydroxymitragynine (7-OH) is an alkaloid compound that acts as a mu-opioid receptor agonist [5]. It occurs naturally in trace amounts—typically less than 2% of total alkaloid content—in the leaves of Mitragyna speciosa, commonly known as kratom [6]. Recent regulatory attention has focused on products containing synthetic or highly concentrated forms of 7-OH, which differ substantially from traditional kratom preparations.

    The Critical Distinction

    Natural Kratom

    • • Contains <2% 7-OH alkaloids
    • • Balanced alkaloid profile
    • • Traditional herbal use
    • • Not targeted by FDA recommendation

    Synthetic/Concentrated 7-OH

    • • Up to 13x more potent than morphine
    • • Isolated or synthesized compound
    • • Marketed as "enhanced kratom"
    • • Subject of FDA Schedule I recommendation

    Reports from poison control centers and healthcare providers have documented cases of dependence and withdrawal associated with concentrated 7-OH products [7]. Clinical presentations have included symptoms consistent with opioid withdrawal, though the full scope of effects remains under study. More research is needed to fully characterize the pharmacology and long-term health impacts of these products.

    Federal Classification Efforts

    FDA's July 2025 Recommendation

    On July 29, 2025, the FDA issued a recommendation to the DEA proposing Schedule I classification for 7-hydroxymitragynine [1]. The agency's decision was based on:

    • Pharmacological analysis of 7-OH's opioid receptor activity
    • Review of adverse event data from poison control centers and healthcare facilities
    • Assessment of abuse potential and lack of FDA-approved medical use
    • Input from stakeholders including consumer advocacy groups and industry representatives

    FDA Statement (July 29, 2025)

    "This recommendation follows a thorough medical and scientific analysis by the FDA and is one of several efforts to address the agency's concerns around dangerous products that contain or are disguised or marketed as kratom."

    Source: FDA Press Release

    What Schedule I Classification Means

    If the DEA accepts the FDA's recommendation, 7-OH would be classified alongside:

    Heroin

    Diacetylmorphine

    LSD

    Lysergic acid diethylamide

    MDMA

    Ecstasy/Molly

    State and Local Legislation

    Florida's State-Level Classification (August 2025)

    On August 13, 2025, Florida implemented an emergency rule classifying 7-hydroxymitragynine as a Schedule I controlled substance under state law [2]. This action:

    • Prohibited the sale and distribution of 7-OH products in Florida
    • Established criminal penalties for violations consistent with other Schedule I substances
    • Represented the first state-level emergency classification of 7-OH
    • May inform regulatory approaches in other jurisdictions

    Florida AG Statement

    "We are immediately removing dangerous 7-OH from store shelves to protect Florida families from this synthetic opioid threat."

    Attorney General James Uthmeier, August 13, 2025

    New York State Legislation

    Senate Bill S7379 (2025) proposes adding kratom and its primary active alkaloids—including concentrated 7-OH—to New York's list of Schedule I controlled substances. Key provisions include:

    • Schedule I classification for synthetic and concentrated 7-OH products
    • Mandatory warning labels on kratom-containing products
    • Ban on misleading "all natural" claims for products with added 7-OH
    • Minimum purchase age of 21 for kratom products

    Suffolk County Local Law (Already in Effect)

    Local Law No. 37-2016 already prohibits the sale or distribution of kratom products—including 7-OH derivatives—to individuals under the age of 21 in Suffolk County, New York. This law has been in effect since 2016 and includes:

    • Age verification requirements for retailers
    • Civil and criminal penalties for violations
    • Authority for local law enforcement to confiscate non-compliant products

    Other New York Counties with Kratom Restrictions

    Suffolk County

    Age 21+ requirement since 2016

    Nassau County

    Currently under review

    Health Risks of 7-OH Products

    Reported Health Concerns

    Acute Effects

    • • Respiratory depression [8]
    • • Sedation and drowsiness
    • • Potential interactions with central nervous system depressants
    • • Nausea and vomiting
    • • Cognitive impairment

    Long-term Considerations

    • • Physical dependence with regular use [9]
    • • Withdrawal symptoms upon discontinuation
    • • Tolerance development requiring increased doses
    • • Limited data on long-term health outcomes
    • • Uncertain safety profile with prolonged use

    Note on Evidence: Most clinical data on 7-OH effects comes from case reports and poison control center data rather than controlled clinical trials [10]. Further research is needed to fully characterize health risks and establish evidence-based treatment protocols.

    Clinical Reports and Surveillance Data

    Healthcare providers and poison control centers have documented increasing reports of adverse events associated with concentrated 7-OH products [7]:

    Reported Case Trends

    • • Withdrawal presentations consistent with opioid agonist cessation
    • • Reports of dependence developing with regular use
    • • Emergency department visits involving 7-OH products have increased
    • • Many users report being unaware of product composition and potency

    Source: Surveillance data from regional poison control centers, 2023-2025 [11]

    Poison Control Surveillance

    National poison control data shows increased exposure reports for products labeled as containing 7-OH [12]:

    • 2023: Baseline reporting period
    • 2024: Notable increase in exposure reports
    • 2025: Continued upward trend through August

    Data Limitations: Exposure reports reflect calls to poison control centers and may not capture all adverse events. Underreporting is common in substance use surveillance systems.

    Considerations for Long Island Residents

    Several factors relevant to Long Island residents include:

    • Product availability: 7-OH-containing products have been sold in retail locations including smoke shops and convenience stores
    • Labeling concerns: Products may be marketed as "herbal supplements" without clear disclosure of synthetic content
    • Regulatory status: Suffolk County has age restrictions; state-level regulations under consideration
    • Information access: Public awareness of product composition and potential risks remains limited

    Support Resources in Nassau & Suffolk Counties

    If you are concerned about substance use involving 7-OH or other compounds, clinical support is available:

    Medical Assessment Programs

    Healthcare providers can assess symptoms and provide clinical guidance

    → View assessment options

    Nassau County Resources

    Treatment facilities and support services

    → View Nassau resources

    Suffolk County Resources

    Local treatment programs and clinical services

    → View Suffolk resources

    Crisis Support

    Confidential support available

    → Call 844-DETOXNY (844-338-6969)

    Regulatory Timeline and Outlook

    Q4

    Q4 2025

    DEA review of FDA recommendation; potential public comment period

    Q1

    Q1 2026

    Possible implementation of federal classification if approved

    NY

    New York State Legislation

    Senate Bill S7379 under review; implementation timeline uncertain

    References

    1. U.S. Food and Drug Administration. (2025, July 29). FDA Takes Steps to Restrict 7-OH Opioid Products Threatening American Consumers.https://www.fda.gov
    2. Florida Office of the Attorney General. (2025, August 13). Attorney General Files Emergency Rule Regarding 7-Hydroxymitragynine. Press release.
    3. Suffolk County, New York. (2016). Local Law No. 37-2016: Prohibiting the sale of kratom to persons under twenty-one years of age.
    4. International Society of Substance Use Professionals. (2025). Substance Use Surveillance Report.https://www.issup.net
    5. Váradi, A., et al. (2016). Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism. Journal of Medicinal Chemistry, 59(18), 8381-8397.
    6. Prozialeck, W. C., et al. (2012). Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. Journal of the American Osteopathic Association, 112(12), 792-799.
    7. American Association of Poison Control Centers. (2025). National Poison Data System Annual Report.
    8. Eastlack, S. C., et al. (2020). Kratom—Pharmacology, clinical implications, and outlook: A comprehensive review. Pain Physician, 23, 145-168.
    9. Coe, M. A., et al. (2019). Kratom as a substitute for opioids: Results from an online survey. Drug and Alcohol Dependence, 202, 24-32.
    10. Henningfield, J. E., et al. (2018). Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users. Drug and Alcohol Dependence, 183, 134-140.
    11. Regional Poison Control Centers. (2023-2025). Surveillance Data on Kratom and 7-OH Exposures. Unpublished data.
    12. National Poison Data System. (2025). Trends in Kratom and Novel Alkaloid Exposures. Annual surveillance report.

    Note on Sources: This article synthesizes information from government regulatory agencies, peer-reviewed scientific literature, and public health surveillance systems. Where clinical evidence is limited or emerging, this has been noted in the text. References reflect sources available as of November 2025.

    Related Articles & Resources

    Frequently Asked Questions

    Get answers to common questions about our 24/7 crisis helpline and addiction support services.

    Still have questions? Our crisis counselors are available 24/7.

    Call 844-338-6969

    Related Resources

    Recovery Support Network

    Long Island Rehab Helpline & Crisis Intervention connects families with trusted clinical resources across New York.

    Our network includes: Intervention NY, Every1 Center, HVATC, and Long Island Addiction Treatment Resources